Drug manufacturer AstraZeneca has ordered four more APAS Independence laboratory instruments from AI microbiology automation manufacturer Clever Culture Systems, formally known as LBT Innovations. The order, worth $3.1 million over seven years, adds to the five APAS instruments already in use by the global pharmaceutical company, where they monitor for bacterial contamination in the company’s…
Microbiology automation company LBT Innovations has sold five APAS Independence laboratory instruments to pharmaceutical manufacturer AstraZeneca AB and will provide maintenance and support services over seven years. The total contract value is worth up to $4.1 million depending on the level of services required, and is in addition to the lease of a sixth instrument…
Laboratory automation manufacturer LBT Innovations has announced that its APAS PharmaQC automated pharmaceutical manufacturing quality control system was now commercially ready after an extensive period of R&D. Primary validation of the device has been completed and the technology formally released to pharmaceutical manufacturer AstraZeneca, a partner in the development. APAS PharmaQC provides automated imaging, analysis…
Microbiology diagnostic equipment manufacturer LBT Innovations has fully written down the value of its major business centred on its APAS technology. The company has recognised a non-cash impairment of $13.4 million which is the full carrying value of the company’s intangible assets related to APAS, as well as a non cash write off of around…
